Provided by Tiger Trade Technology Pte. Ltd.

BRII-B

1.030
+0.0201.98%
Volume:373.00K
Turnover:372.82K
Market Cap:743.66M
PE:-2.86
High:1.030
Open:1.015
Low:0.970
Close:1.010
52wk High:2.340
52wk Low:0.900
Shares:722.00M
HK Float Shares:722.00M
Volume Ratio:0.32
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.360
ROE:-7.67%
ROA:-6.42%
PB:0.29
PE(LYR):-2.86
PS:11.12

Loading ...

Wuxi XDC Appoints Yuan Fang Joint Company Secretary, Authorized Representative

Reuters
·
Jun 26

HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%

Tiger Newspress
·
Jun 23

Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million

Reuters
·
Jun 17

BRII-B Announces Share Buyback Initiative

Stock News
·
Jun 17

Brii Biosciences Announces HK$60 Million On-Market Share Buy-back, Capping at 10% of Issued Shares

Bulletin Express
·
Jun 17

Brii Biosciences - to Buy Back up to 10% of Issued Shares

THOMSON REUTERS
·
Jun 17

Brii Biosciences Ltd - Share Buy-Back Programme Is No More Than HK$60 Mln

THOMSON REUTERS
·
Jun 17

Brii Biosciences shareholders adopted resolutions at annual general meeting, poll results show

Reuters
·
Jun 16

HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%

Tiger Newspress
·
Jun 05

Brii Bio says Phase 2 ENSURE trial shows higher HBV functional cure rate with elebsiran plus pegylated interferon alfa

Reuters
·
May 27

BRII-B (02137) and Vir Yet to Settle Claims in Ongoing Dispute

Stock News
·
May 22

BRII-B Initiates Arbitration Against Vir Biotechnology, Casting Uncertainty Over Elebsiran Hepatitis B Program

Bulletin Express
·
May 22

Brii Biosciences Ltd - as of May 22, Arbitration Between Brii and Vir Remains in Early Stages With No Resolution

THOMSON REUTERS
·
May 22

Brii Biosciences Ltd - Considers Elebsiran Program Future Uncertain Due to Ongoing Dispute

THOMSON REUTERS
·
May 22

Brii Biosciences - Cannot Invest in Phase 3 Clinical Study of Any Elebsiran-Containing Combination Therapy for Hbv Until Claims Are Resolved

THOMSON REUTERS
·
May 22

Brii Biosciences says arbitration with Vir clouds elebsiran hepatitis B program future

Reuters
·
May 22

Biotech Stocks Plunge Amid Global Bond Selloff and Rising Interest Rate Concerns

Stock News
·
May 18

HK Movers | Biotech Stocks Jump. InnoGen up over 44%; Clover Bio up over 11%; Junshi Bio up 9%; Laekna up 8%; Asymchem up over 3%; Tigermed up 2%

Tiger Newspress
·
May 11

Brii Biosciences Issues 47,409 New Shares in April; Public Float Remains Above 25% Threshold

Bulletin Express
·
May 06

HK Movers | Biotech Stocks Jump. Wuxi Apptec Soars 14% as 1Q Net Profit Rises 26.7%; Junshi Bio up 8%; Asymchem up Nearly 7%; Pharmaron up 4%

Tiger Newspress
·
Apr 28